Frans van Houten is CEO of Royal Philips, a position he has held since April 2011. He is also Chairman of the Board of Management and the Executive Committee.
He is passionate about innovation, entrepreneurship and business transformation to drive competitiveness and customer value. He is extending Philips’ leadership in health technology as the company focuses on its mission to make the world healthier and more sustainable, with the goal of improving three billion lives per year by 2025.
Frans drives Philips’ strategic agenda to provide healthcare technology solutions in support of seamless, patient-centered care across the health continuum, starting with healthy living and prevention, precision diagnosis and personalized treatment, through to care in the home – where the cycle to healthy living begins again. He leads the company’s initiatives to help empower consumers to take more care of their own health and to provide healthcare solutions – suites of systems, smart devices, software and services – to customers and health systems.
He first joined Philips in 1986 and has held multiple global leadership positions across the company on three continents, including the role of co-CEO of the Consumer Electronics division. Frans’ team has driven the transformation and revitalization of the Philips portfolio to become a focused health technology company through targeted divestment, acquisition and organic business development. This is exemplified by the sale of the television business in 2012; the audio and video businesses in 2014 and the IPO of Philips Lighting on the Amsterdam Euronext stock exchange in May 2016. At the same time, Philips has invested in a number of acquisitions that strengthen the company’s portfolio, among them medical device leaders Volcano and Spectranetics, respiratory care leader RespirTech, and population health management leaders Wellcentive and VitalHealth, as well as others in digital pathology, neurology, pregnancy & parenting, healthcare informatics and ultrasound. He’s also driven increased investment in R&D to establish new businesses in areas like digital pathology, medical wearables and healthcare informatics.